The FAZ published a background article on the active M&A environment in medtech despite (and partially even supported by) the market conditions with a specific focus on the Siemens Healthineers / Varian Medical Systems transaction. Hubertus Leonhardt, managing partner of SHS, has been quoted regarding the current pricing in M&A transactions for healthcare companies.

How has the medical technology industry developed in comparison to the overall economy in recent years? The Schwäbische Zeitung (https://www.schwaebische.de) reports on the SHS Medical Technology Index.

SHS sees medical technology back on track for success in Germany in 2019 Medical technology sector increases turnover by 10% in 2019 In spite of COVID-19, SHS expects the medical technology industry to outperform the German economy as a whole in 2020 as well Effects of the EU Medical Device Regulation (MDR) not yet digested […]

In the spring, we invested in Finnish medical technology company Neuro Event Labs Oy as part of an international consortium. With its product Nelli™, the health tech specialist from Tampere has developed an AI-powered epilepsy diagnostic tool that can be used by patients at home. Epilepsy is one of the most common neurological disorders, affecting […]

Medical technology is a highly dynamic, global growth market. Anyone interested in getting detailed information about this key market should download the Market Study Medical Technology 2020 published by Clairfield International. In addition to renowned organisations such as the German Medical Technology Association (BVMed) and the Working Group Medical Technology of the Mechanical Engineering Industry […]

On June 19, 2020, our Swiss portfolio company Advanced Osteotomy Tools (AOT) successfully completed the last surgery required for the first-in-man clinical study of its proprietary CARLO® system. Given the small delay due to COVID-19, we are now all the more pleased with the outcome. This takes the CARLO® (Cold Ablation Robot-guided Laser Osteotome) system […]

On April 1, 2020, Sascha Alilovic was appointed Managing Partner of SHS. Since he joined SHS in 2018, SHS investors and portfolio companies have appreciated his expertise in the international life science industry and his experience in strategic transactions for national and international medical technology companies. For more information on Sascha Alilovic, click here.

The Red Dot Award is like the Oscar for product design. We would like to congratulate our portfolio company TRI® Dental Implants on its Red Dot Award for the world’s first digital implant matrix®. With this new kind of implant connection, dentists can plan the prosthetics for their patients directly on the implant, without an […]

The PiCSO® system is a milestone for heart attack patients and was awarded the coveted EU CE mark for medical products a few days ago. Every minute counts during a heart attack. Procedures undertaken in the cardiac catheter laboratory, where minimally invasive examinations and interventions on the heart are performed, are extremely challenging. Reducing the […]

Engineer Heinz Jacqui has successfully held management positions in international medical technology companies for more than 30 years. Since June 1, 2020, Heinz Jacqui has been bringing his strategic experience to bear at SHS by helping to review new portfolio companies in the fields of cardiology, imaging and intensive care. For more information on our […]

We’re sure some of you have already visited the new SHS website that went live in spring. Clearly structured and optimised for use on mobile devices, the new website contains information on our portfolio companies, investment strategy and investment funds and, of course, the latest news on all the activities of SHS and the companies […]

A real improvement in kidney transplant rejection diagnostics: The transplantation of a organ (e.g. kidney) is a highly invasive procedure, a high risk but also chance for the patient and a huge burden for the body to process. Furthermore, current standards of diagnosis for the rejection risk of transplanted kidneys are invasive, not robust, and an additonal burden for the patient. This is changing now by using NMR spectroscopy as a reliable and cost efficient non invasive alternative. Would it not be good to have access to such methodology as a standard?